Human Vaccines – 2018 Global Strategic Business Report Covering 2016-2024: Increasing Need for Vaccine Promotion in Developing Regions

Dublin, Nov. 15, 2018 (GLOBE NEWSWIRE) -- The "Human Vaccines - Global Strategic Business Reports" report has been added to's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Human Vaccines by the following Product Segments:

  • Pediatric Vaccines
  • Adult Vaccines

Company profiles are primarily based on public domain information including company URLs.

The report profiles 66 companies including many key and niche players such as:

  • ALK
  • Abell A/S (Denmark)
  • Altimmune, Inc. (US)
  • Bavarian Nordic A/S (Denmark)
  • BiondVax Pharmaceuticals Ltd. (Israel)
  • Bharat Biotech International Limited (India)
  • GlaxoSmithKline Plc. (UK)
  • Hualan Biological Engineering Inc. (China)
  • Janssen Pharmaceuticals, Inc. (US)
  • MedImmune (US)
  • Merck & Co., Inc. (US)
  • Pfizer Inc. (US)
  • Sanofi Pasteur SA (France)
  • Serum Institute of India Pvt. Ltd. (India)
  • Shanghai BravoBio Co., Ltd. (China)
  • Seqirus (UK)
  • SK Chemicals Co., Ltd. (Korea)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Zydus Cadila (India)

Key Topics Covered


  • Human Vaccines: A Prelude
  • Human Vaccines Market
  • A Snapshot
  • Market Dynamics
  • Growth Drivers in a Capsule
  • Developed World: The Key Markets
  • Emerging Markets: The Future Growth Area
  • Vaccine Pricing: The Developed
  • Developing Divide


  • Prophylactic Pediatric Vaccines
  • A Mature Market
  • Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers
  • Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines
  • Novel Vaccines against Emerging Infectious Diseases
  • Ongoing Developments for a Vaccine against Zika Virus
  • Sanofi's Dengue Vaccine First-to-Market
  • Pipeline & Marketed Dengue Vaccine: 2016
  • Computational Tools Come to Aid in Development of Ebola Vaccines
  • Vaccine for AIDS
  • Ongoing Research for HIV Vaccine & Commercial Pipeline
  • List of Clinical Trial (Phase II) AIDS Vaccines: 2015
  • Staggering Global Statistics of AIDS
  • Opportunity Indicator
  • Vaccination-Autism Link and Other Safety Concerns Thwarted
  • Threat of Pandemic Rejuvenates Vaccine Market
  • Influenza Vaccines on a Growing Spree
  • Influenza Vaccines on the Current Market: 2016
  • H1N1 Vaccines Hit the Market in August 2009
  • H1N1 Influenza Vaccines and Manufacturers
  • Influenza Market Faces Several Challenges
  • Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market
  • Unmet Demand for TB Vaccine
  • Key TB Vaccine Candidates in the Pipeline: 2016
  • Need for a Human Vaccine for Leishmaniasis
  • Economic Factors Hamper Optimal Vaccine Development and Delivery
  • Increasing Need for Vaccine Promotion in the Developing Regions
  • Changing Vaccine Needs
  • Religious Concerns over Immunizing Young Girls against Human Papillomavirus
  • Changing Travel Patterns Increase Demand for Hepatitis B Vaccine
  • DNA Vaccines: Engineering Growth
  • Noninjectable Vaccines: Gain without Pain
  • Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines
  • Conjugate Vaccines: A Technological Innovation
  • Hib Vaccines on the Market: 2016
  • Growing Pricing Pressure
  • A Major Market Deterrent
  • Safety Issues Come to the Fore
  • BioWarfare: Threat Perception and Preparedness
  • Overview of Potential Bio-Terrorist Agents
  • Smallpox (Variola Major)
  • Anthrax (Bacillus Anthracis)
  • Plague (Yersinia Pestis)
  • Botulism (Clostridium Botulinum)
  • Tularemia (Francisella Tularensis)
  • Tackling Cold Chain Issues
  • Trade Statistics


  • Pfizer Scores Big with Prevnar
  • Trumenba Shows Promise in Phase III Clinical Trials
  • GSK Takes Big Leap into the Meningococcal Vaccine Market
  • Acquired Products Strengthen GSK's Vaccines Sales
  • The Potential for MenABCWY Vaccine
  • Sanofi Works on Production Issues to Boost Sales
  • New Vaccines to Enhance Prospects for Sanofi
  • Sanofi's Human Vaccine R&D Pipeline
  • Weaker Sales Drive Merck and Sanofi's European JV Split
  • Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market



  • Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine
  • Takeda Begins Phase2b Trial for World's First Norovirus Vaccine
  • Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine
  • Investigational Vaccine for P.vivax Malaria Enters Human Trials
  • Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficile
  • Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine
  • Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine
  • Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies
  • Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial


  • FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok
  • Sanofi's Dengue Vaccine Approved in Costa Rica
  • GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line
  • FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine
  • China Launches HFMD Vaccine
  • Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection
  • Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection
  • WHO Accepts Merck's Investigational Ebola Vaccine Application for Review
  • Sanofi's Dengvaxia Receives Marketing Authorization in Mexico
  • SK Chemicals Launches Influenza Vaccine SKYCellflu
  • Sanofi Pasteur Ships First Doses of Fluzone for the US Market
  • Bharat Biotech Launches Made-in-India ROTAVAC Vaccine


  • WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13
  • Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility
  • Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government
  • Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines
  • WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue
  • Kaketsuken to Sell Vaccines Business to Astellas
  • Sanofi and Merck End Joint Venture on Vaccines
  • GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine
  • Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA
  • Bavarian Nordic Enters into License Agreement with Janssen
  • CSL Rebrands Influenza Vaccines Business as Seqirus
  • MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D
  • GlaxoSmithKline Acquires Novartis' Vaccines Business
  • Vaxin Changes Name to Altimmune
  • Takeda Expands Commercialization Agreement with Nanotherapeutics
  • MedImmune Enters Into License Agreement with Inovio Pharmaceuticals
  • CSL Completes Acquisition of Novartis' Influenza Vaccines Business
  • Pfizer to Acquire Meningitis Vaccines from GSK
  • Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License



Total Companies Profiled: 63 (including Divisions/Subsidiaries 72)

The United States (22)

Canada (1)

Japan (5)

Europe (14)

  • France (3)
  • Germany (2)
  • The United Kingdom (2)
  • Spain (1)
  • Rest of Europe (6)

Asia-Pacific (Excluding Japan) (28)

Latin America (1)

Middle East (1)

For more information about this report visit

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines